LUPUS 2025: Lupus Research Alliance and Lupus Therapeutics Highlights
The Lupus Research Alliance (LRA) and clinical affiliate Lupus Therapeutics (LT) are proud sponsors and participants of this week’s 16th International Congress on Systemic Lupus Erythematosus (LUPUS 2025). The global conference convenes leading experts in rheumatology, immunology and autoimmune research to discuss the latest advancements in lupus. This year, the meeting, being held May 21-24 […]
Lupus Innovation Award (LIA)
The Lupus Innovation Award ($300,000 for 2 years) provides early-stage support for highly innovative approaches to major challenges in lupus research. If you are a researcher and would like to learn more about our funded research please click here.
Lupus Nephritis: A Major Focus at the Lupus Research Alliance
Updated March, 2022 Developing safe and effective treatments for lupus nephritis has been an urgent and long-standing goal in the lupus community. As the leading private funding agency for lupus research, the LRA and its legacy organizations have dedicated significant focus and resources towards addressing this continued challenge, awarding over 40 grants to address this […]
Good News on Lupus Nephritis Discoveries from ACR Convergence 2020
November 19, 2020 The LRA is proud to share the extraordinary work presented at ACR Convergence 2020 by research members of the Accelerating Medicines Partnership Rheumatoid Arthritis (RA) and Systemic Lupus Erythematosus (SLE) program (AMP RA/SLE). AMP is a public-private partnership between the National Institutes of Health (NIH), eight biopharmaceutical companies, the LRA and several […]
Lupus Research Alliance Grants Lupus Innovation Awards to Advance Ground-Breaking Lupus Research
NEW YORK, NY, March 23, 2023. The Lupus Research Alliance (LRA) today announced the recipients of the newest Lupus Innovation Award (LIA) grants. Collectively, the seven projects led by research teams from the U.S. and Europe explore multiple components of lupus, focusing on its causes and the development of more personalized approaches to lupus treatments. […]
Lupus Research Alliance Grants Lupus Innovation Awards to Eleven Talented Researchers to Accelerate Pace of Discovery in Lupus Research
The Lupus Research Alliance (LRA) is proud to announce the recipients of this year’s Lupus Innovation Award (LIA), addressing many critical themes in lupus research including novel therapeutic strategies, the impact of chronic inflammation, and the identification of biomarkers for improved diagnosis and monitoring. These prestigious grants provide investigators from around the world with up […]
Lupus Therapeutics Announces Collaboration to Support the Evaluation of Non-Genetically Modified Cell-Based Therapy for Lupus Nephritis with Artiva Biotherapeutics
Lupus Therapeutics, the clinical research affiliate of the Lupus Research Alliance, announced a collaboration with Artiva Biotherapeutics, Inc. on a Phase 1 trial of the company novel NK cell-based therapy AlloNK® (also known as AB-101), in combination with anti-CD20 antibodies, for patients with active lupus nephritis – inflammation of the kidneys caused by lupus. AlloNK […]
Lupus Research Alliance Awards $3 Million to Advance Pediatric Lupus Nephritis Diagnosis and Treatment
The Lupus Research Alliance (LRA) is pleased to announce that the 2023 Global Team Science Award (GTSA) has been granted to an exceptional multidisciplinary research team of experts in immunology, pediatric rheumatology and nephrology, genetics, and data analysis to identify drivers of lupus nephritis in children with the aim of improving its diagnosis and treatment. […]
Lupus Research Alliance Announces Lupus Research Highlights at ACR Convergence 2024
The Lupus Research Alliance (LRA), the largest private funder of lupus research worldwide, today announced that 34 presentations, including research funded by the organization or supported by its clinical research affiliate Lupus Therapeutics, will be part of ACR Convergence 2024. The annual meeting of the American College of Rheumatology takes place November 14-19, at the […]
Lupus Research Alliance Grants Lupus Innovation Awards to Nine International Researchers Pushing the Boundaries of Lupus Research
The Lupus Research Alliance (LRA) is proud to announce that nine international researchers are the recipients of this year’s Lupus Innovation Award (LIA). They will conduct innovative research to uncover the underlying mechanisms and identify novel targets and pathways that could be harnessed to predict, monitor, and treat lupus, a complex autoimmune disease. The LIA […]
Lupus Research Alliance Response to Positive Trial Testing Obinutuzumab (Gazyva®) for Lupus Nephritis
NEW YORK, Nov. 10, 2019 /PRNewswire/ — The Lupus Research Alliance (LRA) is pleased to acknowledge positive results presented by Genentech at the American Society of Nephrology (ASN) and the 2019 ACR/ARP Annual Meeting showing the effectiveness of obinutuzumab (Gazyva®), a type I anti-CD20 monoclonal antibody, in the Phase 2 NOBILITY trial for the most severe […]
Lupus Research Alliance Applauds Phase III Trial Results for Potential Lupus Nephritis Treatment
December 4, 2019 The Lupus Research Alliance congratulates Aurinia Pharmaceuticals on achieving the first positive Phase III trial results for an urgently needed treatment for lupus nephritis. The company’s investigational drug voclosporin showed positive effectiveness and good safety for treating lupus nephritis in combination with standard therapy. “Lupus nephritis is one of the most common […]